The Main Metabolites of Fluorouracil + Adriamycin + Cyclophosphamide (FAC) Are Not Major Contributors to FAC Toxicity in H9c2 Cardiac Differentiated Cells

In the clinical practice, the combination of 5-fluorouracil (5-FU) + Adriamycin (also known as doxorubicin, DOX) + cyclophosphamide (CYA) (known as FAC) is used to treat breast cancer. The FAC therapy, however, carries some serious risks, namely potential cardiotoxic effects, although the mechanisms...

Descripción completa

Detalles Bibliográficos
Autores principales: Reis-Mendes, Ana, Carvalho, Félix, Remião, Fernando, Sousa, Emília, Bastos, Maria de Lourdes, Costa, Vera Marisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6468772/
https://www.ncbi.nlm.nih.gov/pubmed/30862114
http://dx.doi.org/10.3390/biom9030098

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6468772/
https://www.ncbi.nlm.nih.gov/pubmed/30862114
http://dx.doi.org/10.3390/biom9030098

Ejemplares similares